BioMarin readies pivotal breast cancer trial; Maxygen to liquidate;

@FierceBiotech: PR: 1st clinical data presented with ImmunoGen's IMGN853, potential new ovarian cancer therapy. Release | Follow @FierceBiotech

@JohnCFierce: GlaxoSmithKline grabs PhII rheumatoid arthritis drug in MorphoSys deal. Article | Follow @JohnCFierce

@RyanMFierce: Monday at ASCO marked by bad news from $SNY, $LLY after feel-good weekend for $MRK, $BMY. | Follow @RyanMFierce

@EmilyMFierce: New agent stops replication of hep C virus in preclinical studies. Article | Follow @EmilyMFierce

> BioMarin ($BMRN) laid out promising results for its PARP inhibitor BMN673. Investigators say that it was effective in treating patients with breast or ovarian cancer caused by BRCA mutations. The results set the stage for a pivotal trial on metastatic breast cancer, slated to begin later this year. Story

> Maxygen ($MAXY) is taking up residence at the biotech graveyard. The company's board has voted to liquidate the company. Release

> Aeterna Zentaris ($AEZS) says it gathered encouraging final data for the Phase I portion of an ongoing Phase I/II trial with Zoptarelin Doxorubicin (AEZS-108) in prostate cancer. Release

Medical Device News

@FierceMedDev: Mayo Clinic: Metabolomics could be key to early Alzheimer's blood Dx test. Article | Follow @FierceMedDev

@DamianFierce: Patient selection, biomarkers are key to cancer R&D, Quintiles says. Story | Follow @DamianFierce

@MichaelGFierce: Medtronic triggers summer PMA process for drug-eluting balloon. More | Follow @MichaelGFierce

> WHO approves low-tech Israeli circumcision device. News

> Medtronic triggers summer PMA process for drug-eluting balloon. Article

> Mayo Clinic: Metabolomics could be key to early Alzheimer's blood Dx test. More

> Cochlear downgrades profit forecast as clients await next-gen hearing aid. Story

Pharma News

@FiercePharma: In which hep C drugs Incivek and Victrelis go from hit to dud in two years. Report | Follow @FiercePharma

@EricPFierce: Dr. Reddy's, Fujifilm pull plug on Japanese joint venture. Article | Follow @EricPFierce

@CarlyHFierce: ICYMI Friday: Sun Pharma eyeing takeover of Sweden's Meda. Story | Follow @CarlyHFierce

> ASCO: Bayer's Nexavar gets boost, while Roche's Avastin reports mixed. Roundup

> Lilly blockbuster Alimta burned by more disappointing news. More

> KV rebounds as docs get uneasy about compounded drugs. Story

CRO News

> Quintiles: Patient selection, biomarkers key to cancer R&D. Report

> Unither buys UCB's NY plant. Item

> DKSH ups South Korean presence. Story

> QPS teams with Hepregen for DMPK. More

> UPM buys Pfizer's TN plant, snags CMO deal. Article

Biotech IT News

> Software-backed MTI system spots breast tumors. Item

> OpGen teams with bioinformatics outfit to combat outbreaks. Story

> BT and Accelrys deepen ties for cloud computing in life sciences. Report

> Eli Lilly backs mobile app for cancer docs. News

> Boehringer, Eli Lilly aim to educate diabetics with iPad game. Article

And Finally… The death toll from a deadly new virus continues to rise. Story

 

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.